- Home
- ARCC vs ICLR Comparison
ARCC vs ICLR Comparison
Compare ARCC & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARCC
- ICLR
- Stock Information
- Founded
- ARCC 2004
- ICLR 1990
- Country
- ARCC United States
- ICLR Ireland
- Employees
- ARCC N/A
- ICLR N/A
- Industry
- ARCC Finance/Investors Services
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ARCC Finance
- ICLR Health Care
- Exchange
- ARCC Nasdaq
- ICLR Nasdaq
- Market Cap
- ARCC 15.8B
- ICLR 13.7B
- IPO Year
- ARCC 2004
- ICLR 1998
- Fundamental
- Price
- ARCC $21.09
- ICLR $175.21
- Analyst Decision
- ARCC Buy
- ICLR Buy
- Analyst Count
- ARCC 9
- ICLR 15
- Target Price
- ARCC $23.00
- ICLR $209.93
- AVG Volume (30 Days)
- ARCC 3.7M
- ICLR 1.0M
- Earning Date
- ARCC 10-29-2025
- ICLR 10-22-2025
- Dividend Yield
- ARCC 9.11%
- ICLR N/A
- EPS Growth
- ARCC N/A
- ICLR 13.11
- EPS
- ARCC 2.03
- ICLR 9.73
- Revenue
- ARCC $3,011,000,000.00
- ICLR $8,089,820,000.00
- Revenue This Year
- ARCC $3.21
- ICLR N/A
- Revenue Next Year
- ARCC $5.09
- ICLR $1.73
- P/E Ratio
- ARCC $10.37
- ICLR $17.78
- Revenue Growth
- ARCC 6.85
- ICLR N/A
- 52 Week Low
- ARCC $18.26
- ICLR $125.10
- 52 Week High
- ARCC $23.84
- ICLR $310.54
- Technical
- Relative Strength Index (RSI)
- ARCC 24.00
- ICLR 53.21
- Support Level
- ARCC $21.02
- ICLR $164.00
- Resistance Level
- ARCC $22.50
- ICLR $177.00
- Average True Range (ATR)
- ARCC 0.25
- ICLR 6.69
- MACD
- ARCC -0.13
- ICLR -0.71
- Stochastic Oscillator
- ARCC 4.70
- ICLR 65.56
About ARCC Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.